$CIIX Returns to Roots as Financial Services Business Focusing on Blockchain and Cryptocurrency

March 9, 2018

• Company returning to its roots in financial consulting, corporate brand building and educational services for cryptocurrencies, such as bitcoin
• CIIX has daily video from NYSE targeted at its global Chinese-speaking investment community titled ‘Bitcoin MultiMillionaire’ and hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters
• Company is urging its shareholders to convert stock, on a four-for-one basis, for a share in the new, private company that includes hemp assets CBD Biotechnology Co. Ltd., Hemp Logic, Inc. and ChineseHempOil.com, Inc.

ChineseInvestors.com, Inc. (OTCQB: CIIX) will return to its roots as a financial consultant and a specialist in cryptocurrency, especially bitcoin, as it spins off its hemp assets into a private company. In a news release (http://cnw.fm/i7zeW), Paul Dickman, CFO of CIIX, said, “This is a great time to spin off CIIX’s CBD focused assets as we continue to explore new ways to expand its core financial services business, including its recent move into the cryptocurrency and blockchain technology industry.”

CIIX has in the past succeeded as a diverse company with multiple-focuses, but, with this spinoff, it can now concentrate on its core skills in brand building for startups and financial marketing for its clients.

The San Gabriel, California-based company specializes in financial education and marketing for the global Chinese-speaking investment community. It has an interest in the growth of cryptocurrency with a daily video newscast from the NYSE daily titled ‘Bitcoin MultiMillionaire’ and hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters.

Following the planned spinoff, CIIX intends to focus on those interests while giving its shareholders a special dividend. They may exchange four shares of CIIX common for one share in the new company, which consists of CIIX’s hemp-related assets. These include wholly owned foreign enterprise CBD Biotechnology Co., Ltd. and U.S.-based wholly owned subsidiaries Hemp Logic, Inc. and ChineseHempOil.com, Inc.

The four-for-one exchange of shares will be made effective on May 31, 2018, the date of the spinoff. The new company will initially be private, but CIIX has announced plans to bring the new company into the public market in the 12-18 months that follow (http://cnw.fm/MCe3G).

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

• Earth Science Tech, Inc. (ETST) on Course to Complete White Paper Studies in 2019
• Pressure BioSciences Inc.’s (PBIO) New Products and Enhanced Sales Capabilities Drive Plans for Banner 2018
• Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Growing Patent Portfolio Enables Commercialization, Defense of DehydraTECH

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$WATT Receives FCC Certification for its Near Field Wireless Charging Transmitter

Approval signifies the company’s continued momentum in creating a wireless charging ecosystem

$AVXS to be Acquired by Novartis AG for $8.7 billion

• Novartis to acquire AveXis for $218 per share in cash
• AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader
• Transaction expected to be completed in mid-2018

CHICAGO, April 09, 2018 — AveXis, Inc. (NASDAQ:AVXS) announced today that it has entered into an agreement and plan of merger with Novartis pursuant to which Novartis will acquire AveXis for $218 per share or a total of $8.7 billion in cash. This offer represents a premium of 88 percent to AveXis’ closing price on April 6, 2018, and a 72 percent premium to the company’s 30-day volume-weighted average stock price. The transaction was unanimously approved by the Boards of Directors of both companies.

“The commitment, drive and expertise of the entire AveXis team has created significant stockholder value, and we are pleased that Novartis recognizes that value in the potential of AVXS-101, our first in class manufacturing capabilities and our gene therapy pipeline, all of which serve to transform the lives of people devastated by rare and life threatening neurological diseases such as SMA, Rett syndrome and genetic ALS,” said Sean Nolan, President and Chief Executive Officer of AveXis. “With worldwide reach and extensive resources, Novartis should expedite our shared vision of bringing gene therapy to these patient communities across the globe as quickly and safely as possible.”

Novartis plans a smooth transition of AveXis operations and the integration of AveXis’ talented and dedicated employees into the Novartis organization to continue the mission of bringing AVXS-101 to patients worldwide.

Completion of the transaction is expected in mid-2018, pending the successful completion of the tender offer and all other closing conditions. Until that time, AveXis will continue to operate as a separate and independent company.

AveXis’ financial advisors are Goldman Sachs & Co. LLC and Centerview Partners LLC, and Cravath, Swaine and Moore LLP and Cooley LLP are acting as legal counsel for AveXis.

Transaction Details
Under the terms of the agreement and plan of merger, Novartis has formed an acquisition subsidiary, Novartis AM Merger Corporation (“Purchaser”), that will commence a tender offer no later than April 17, 2018, to purchase all outstanding shares of AveXis for $218 per share in cash and AveXis will file a recommendation statement containing the unanimous recommendation of the AveXis board that AveXis stockholders tender their shares to Novartis. Following the completion of the tender offer, Novartis expects to promptly consummate a merger of Purchaser and AveXis in which shares of AveXis that have not been purchased in the tender offer will be converted into the right to receive the same cash price per share as paid in the tender offer (other than shares held by stockholders who properly demand and perfect appraisal rights under Delaware law).

The tender offer and the merger are subject to customary closing conditions, including the tender of at least a majority of outstanding AveXis shares on a fully diluted basis and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.  The merger agreement includes customary termination provisions for both AveXis and Novartis, including a right for either party to terminate if the transactions have not been completed by July 6, 2018 (such date, the “Outside Date”).  Novartis is permitted under specified antitrust related circumstances to extend the Outside Date to October 6, 2018.  If Novartis elects to extend the Outside Date, the offer price will increase from $218 per share to $225 per share in cash.

The merger agreement provides that, in connection with the termination of the merger agreement under specified circumstances, including termination by AveXis to accept a superior proposal, AveXis will be required to pay to Novartis a fee equal to $284 million.  The merger agreement also provides that, in connection with the termination of the merger agreement under specified antitrust related circumstances, Novartis will be required to pay to AveXis a “reverse termination fee” equal to $437 million, which fee increases in the event Novartis elects to extend the Outside Date in accordance with the terms of the merger agreement.

About AveXis, Inc.
AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and SMA Types 2 and 3. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome and a genetic form of amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 (SOD1) gene.

For additional information, please visit www.avexis.com.

IMPORTANT INFORMATION
The tender offer for the shares of outstanding common stock of AveXis has not yet commenced.  This communication is for informational purposes only and does not constitute an offer to buy or a solicitation of an offer to sell any securities of AveXis.  The solicitation and offer to buy common stock of AveXis will only be made pursuant to an Offer to Purchase and related materials.  At the time the tender offer is commenced, Novartis AG and Novartis AM Merger Corporation will file a tender offer statement on Schedule TO with the United States Securities and Exchange Commission (the “SEC”) and thereafter AveXis will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.  INVESTORS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO THE TENDER OFFER OR WHETHER TO TENDER THEIR SHARES PURSUANT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION (INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER) AND THE PARTIES THERETO. Investors may obtain a free copy of the Solicitation/Recommendation Statement and other documents (when available) that AveXis files with the SEC at the SEC’s website at www.sec.gov, or free of charge from AveXis at www.AveXis.com or by directing a request to AveXis at jgoff@avexis.com.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding the completion of the transaction with Novartis. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this communication and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Meaningful factors which could cause actual results to differ from these forward-looking statements include, without limitation:  (i) uncertainties as to the timing of the tender offer and the subsequent merger; (ii) the risk that the tender offer or the subsequent merger may not be completed in a timely manner or at all; (iii) uncertainties as to the percentage of AveXis’ stockholders tendering their shares in the tender offer; (iv) the possibility that competing offers or acquisition proposals for AveXis will be made; (v) the possibility that any or all of the various conditions to the consummation of the tender offer or the subsequent merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement dated April 6, 2018 (the “Merger Agreement”), among Novartis, Novartis AM Merger Corporation and AveXis, including in circumstances which would require AveXis to pay a termination fee; (vii) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on AveXis’ ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (viii) risks related to diverting management’s attention from AveXis’ ongoing business operations; (ix) the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability; and (x) other factors discussed in the “Risk Factors” and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of AveXis’ Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on February 28, 2018, and risks that may be described in Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings by AveXis with the SEC. In addition to the risks described above, other unknown or unpredictable factors also could affect AveXis’ results. As a result of these factors, we cannot assure you that the forward-looking statements in this communication will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication represent our views as of the date of this communication. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this communication. You should read this communication and the documents that we reference in this communication completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
lbarbiero@w2ogroup.com

Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
jgoff@avexis.com

$ETST Reports Record-breaking Sales Revenue in February

March 26, 2018

• ETST revenue increased by 90 percent in the month of February
• Research demonstrates that ETST’s CBD oil offers top nutritional and supplement value
• Newly appointed chief sales officer and chief learning officer opening innovative avenues

Earth Science Tech, Inc. (OTC: ETST) announced on March 13, 2018, that February marked the company’s highest-ever sales revenue month. The innovative biotech company focuses on cannabidiol (CBD) nutraceutical and pharmaceutical fields, along with its provision of R&D for certain medical devices. In February, the company achieved a 90 percent revenue increase, from $39,881 to $75,981. The company attributed this increase to its new veteran chief sales officer, supported by a CBD line that has undergone a revamp (http://cnw.fm/lW7cv).

Earth Science Tech possesses among the highest quality and purity full-spectrum hemp CBD oil on the market. The product is made through critical CO2 extraction processes, making ETST’s CBD oil 100 percent organic and natural. Working alongside DV Biologics and the University of Central Oklahoma, ETST’s research demonstrated that the company is the top nutritional and supplement brand for high-grade hemp CBD oil (http://cnw.fm/U8Jx9).

In a news release, Nickolas Tabraue, company president, director and COO, noted February to be a pivotal month, giving praise to newly appointed CSO Jill Buzan while appointing Gabriel Aviles as the company’s chief learning officer. “Jill Buzan has brought so much to our company, and with her experience and knowledge Earth Science Tech, Inc. truly looks to stay innovative and be the trusted CBD brand in the industry,” Tabraue stated, further mentioning that Aviles has begun recording live videos from Monday through Friday on the company’s YouTube channel. Through this endeavor, individuals will have the opportunity to learn more about CBD and will be able to ask questions in real-time, with the videos being shared on social media.

Commenting on the achievement, CSO Jill Buzan stated, “My first month with the company has been an amazing experience with so much potential. I’m excited to see that we were able to achieve the highest revenue month to date, especially due to product delivery delays and slight errors made from the manufacture.”

Tabraue confirmed that the new product revamp has been successful, despite minor errors and manufacturing delays resulting from the increased product demand that was experienced. “We are currently working on our next batch, improving our formula and providing adequate manufacturing time to eliminate any potential errors and to prevent backorders,” Tabraue continued.

Tabraue goes further to say that ETST’s audit continues to move forward and is set to be finalized before the end of March. The audit will be used to submit the company’s planned Tier II Regulation A+ offering, alongside its planned OTCQB up listing. “The team and I greatly appreciate our stakeholders’ loyalty, trust and support while growing with us. We plan on sharing updates as they progress,” reaffirmed Tabraue. With February proving to be a fiscal milestone for Earth Science Tech, Inc., it can be expected that the newly introduced leadership will bring further innovative changes within this fast-growing industry.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Extracts Maximum Benefit from Cannabis Portfolio
• Strong Leadership Team Guides EVIO, Inc. (EVIO) toward 2018 Goal of Opening 18 Cannabis Testing Labs
• Earth Science Tech, Inc. (ETST) Accelerates the Development and Commercialization of Products

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$DJACF Licensed Cannabis Producer (DOJA) Receives Cannabis Sales License from Health Canada

TORONTO, April 9, 2018 – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE: HIKU), Canada’s first vertically-integrated cannabis brand house, is pleased to announce its wholly owned subsidiary DOJA Cannabis Ltd. (“DOJA“), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“), received an amendment to its license from Health Canada to include the sale of dried cannabis, cannabis plants and seeds, effective April 6, 2018.

“Receiving our license to sell is the crowning milestone in our licensing journey that started in 2013. Becoming only the 28th independent company in Canada with a cannabis sales license under the ACMPR gives Hiku the distinct advantage of being able to showcase and establish the DOJA brand in advance of legal adult-use and retail cannabis sales,” said Alan Gertner, CEO of Hiku.

With over $27 million of available cash and cash equivalents, Hiku is well capitalized to complete its next phase of cannabis production capacity growth. The build-out of Hiku’s second site facility, the “FUTURE LAB”, is well underway and expected to be completed in the summer of 2018, expanding Hiku’s annual production capacity to over 5,000 kg of dried cannabis flower ahead of Canada’s legal adult-use cannabis market.

About Hiku

Hiku is focused on building a portfolio of iconic, engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA‘s ACMPR licensed grow, and Van der Pop‘s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA, is federally licensed to cultivate and sell cannabis pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. Hiku operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include statements regarding the anticipated completion date and production capacity of the Future Lab. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

$GNPX to Present at The MicroCap Conference

AUSTIN, Texas, April 6, 2018 — Genprex, Inc. (NASDAQ:GNPX),  a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that Rodney Varner, Chairman and CEO, will present at The MicroCap Conference to be held in New York City on April 9 and 10, 2018. The Company is scheduled to present on Monday, April 9, 2018 at 4:30 PM EDT.

Mr. Varner will be available for one-on-one meetings.  Interested investors may request a meeting time by contacting Stephanie Carrington at ICR, either by calling 646-277-1282 or via stephanie.carrington@icrinc.com. For more information please visit www.genprex.com.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

About the MicroCap Conference

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors. For more information please visit: www.microcapconf.com or contact Tony Yu at tony@microcapconf.com.

Contact:              

Investors:
Stephanie Carrington
ICR Healthcare
646-277-1282
Stephanie.Carrington@icrinc.com

Media:
James Heins
ICR Healthcare
203-682-8251
James.Heins@icrinc.com

$BWEN Announces Recovery in Order Intake

CICERO, Ill., April 06, 2018 — Broadwind Energy, Inc. (NASDAQ:BWEN) today announced a recovery in the Company’s quarterly order intake. The Company recently booked $10 million in new tower orders and Q1 2018 Gearing segment orders of $15 million, the highest quarterly order intake for the segment since Q2 2014. Consolidated Q1 2018 orders totaled $26 million, the highest since Q1 2017.

Broadwind President and CEO Stephanie Kushner stated, “The oil and gas, and mining industries remain strong.  We continue to diversify our customer base in both Gearing and Heavy Fabrications.  Notably, we are seeing a recovery in tower orders consistent with our expectation of a strong tower market for the mid-term.”

About Broadwind Energy, Inc.
Broadwind Energy (NASDAQ:BWEN) applies decades of deep industrial expertise to innovate integrated solutions for customers in the energy and infrastructure markets. From gears and gearing systems for wind, oil and gas and mining applications, to wind towers and industrial weldments, we have solutions for the energy needs of the future. With facilities throughout the central U.S., Broadwind Energy’s talented team is committed to helping customers maximize performance of their investments—quicker, easier and smarter. Find out more at www.bwen.com

Forward-Looking Statements
This release contains “forward looking statements”—that is, statements related to future, not past, events—as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that reflect our current expectations regarding our future growth, results of operations, financial condition, cash flows, performance, business prospects and opportunities, as well as assumptions made by, and information currently available to, our management. Forward looking statements include any statement that does not directly relate to a current or historical fact. We have tried to identify forward looking statements by using words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “should,” “may,” “plan” and similar expressions, but these words are not the exclusive means of identifying forward looking statements.

Our forward-looking statements may include or relate to our beliefs, expectations, plans and/or assumptions with respect to the following: (i) state, local and federal regulatory frameworks affecting the industries in which we compete, including the wind energy industry, and the related extension, continuation or renewal of federal tax incentives and grants and state renewable portfolio standards; (ii) our customer relationships and our substantial dependency on a few significant customers and our efforts to diversify our customer base and sector focus and leverage relationships across business units; (iii) our ability to continue to grow our business organically and through acquisitions; (iv) the sufficiency of our liquidity and alternate sources of funding, if necessary; (v) our ability to realize revenue from customer orders and backlog; (vi) our ability to operate our business efficiently, manage capital expenditures and costs effectively, and generate cash flow; (vii) the economy and the potential impact it may have on our business, including our customers; (viii) the state of the wind energy market and other energy and industrial markets generally and the impact of competition and economic volatility in those markets; (ix) the effects of market disruptions and regular market volatility, including fluctuations in the price of oil, gas and other commodities; (x) the effects of the recent change of administrations in the U.S. federal government; (xi) our ability to successfully integrate and operate the business of Red Wolf Company, LLC and to identify, negotiate and execute future acquisitions; (xii) the potential loss of tax benefits if we experience an “ownership change” under Section 382 of the Internal Revenue Code of 1986, as amended; and (xiii) the impact of future sales of our common stock or securities convertible into our common stock on our stock price. These statements are based on information currently available to us and are subject to various risks, uncertainties and other factors that could cause our actual growth, results of operations, financial condition, cash flows, performance, business prospects and opportunities to differ materially from those expressed in, or implied by, these statements. We are under no duty to update any of these statements. You should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or other factors that could cause our current beliefs, expectations, plans and/or assumptions to change.

BWEN INVESTOR CONTACT: Joni Konstantelos, 708.780.4819 joni.konstantelos@bwen.com

$NETE Reports Notable 2017 Growth and Achievements, 2018 Goals

April 6, 2018

• Net Element reports 11 percent increase in revenues for 2017
• Company processed $2.8 billion in global transactions during 2017
• Named one of Deloitte’s fastest-growing companies in North America on ‘2017 Technology Fast 500’ list

Having recently reported full-year financial results for 2017 (http://nnw.fm/oJS8A), Net Element, Inc. (NASDAQ: NETE) announced positive progress and achievements for the past year, as well as near future plans as 2018 progresses.

Net Element is a global technology and value-added solutions group engaged in supporting electronic payments acceptance in a multichannel environment, including point-of-sale, e-commerce and mobile devices. Commencing the 2018 year with a healthy balance sheet position, the company announced that it processed more than $2.8 billion in transactions on a global scale during 2017, which represented an increase of 14 percent compared to the previous year. In North America, Net Element processed $2.3 billion in transactions during 2017—an increase of 18 percent over 2016.

The company’s revenues also increased by 11 percent during 2017, reaching $60.1 million. Net Element experienced organic growth across all categories during the year.

Net Element marked significant accomplishments during 2017, including the receipt of a $7.55 million institutional investment to support ongoing organic growth and the company’s blockchain-focused endeavors. Net Element was also listed as one of the fastest-growing companies in North America on Deloitte’s ‘2017 Technology Fast 500’. As part of efforts to offer aid in the wake of Hurricane Irma, the company additionally provided affected Florida small- and medium-sized businesses with free mobile point-of-sale credit card readers.

Net Element also forged various strategic partnerships during 2017, including partnering with Elo to offer a cutting-edge, best-in-class point-of-sale solution and partnering with Payvision in Europe to extend access to global currencies and expand payment acceptance to more than 120 currencies. Net Element additionally joined the Enterprise Ethereum Alliance (EEA) during 2017, which is the largest open-source blockchain initiative in the world.

Last year also featured a variety of product launches and updates for Net Element, including:

• Launch of multichannel payments platform Netevia, which, when fully developed, will enable Net Element to perform in blockchain technology solutions;
• Launch of a web-based, integrated, same-day ACH and e-check processing solution the U.S.;
• Launch of Zero-Fee processing program for SMB merchants in the U.S.;
• Launch of loyalty program for international online merchants using a PayOnline platform;
• Launch of PayOnline support for U.S. e-commerce;
• Launch of Apple Pay support in Russia;
• Launch of payment acceptance module for Telegram, Viber, Facebook and VK instant messenger apps;
• Expansion of payments module to include Prominent InSales platform;
• Launch of comprehensive point-of-sale program during the Unified Payments ‘2017 Launch Series’;
• Launch of ISO incubator program to foster growth and success for certified resellers of Unified Payments;
• Launch of fully integrated payment acceptance for V-Tell;
• Launch of fully integrated payment acceptance for Azimuth Airlines; and
• Addition of support for iDEAL payment system in the Netherlands.

Looking forward, Net Element plans to continue its focus on understanding clients and meeting their payment acceptance needs in core market segments. Other goals include continuing company growth in all key segments, driving client retention, expanding the company’s client base in particular markets, delivering value-added products to increase efficiencies and payment acceptance, continuing the development of Netvia and launching new tools to reach clients and deepen partner relations.

As the global payments industry continues its healthy growth, Net Element believes that new and disruptive technologies will further enable the company to differentiate itself and continue its development and delivery of cutting-edge payment solutions.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Extracts Maximum Benefit from Cannabis Portfolio
• Strong Leadership Team Guides EVIO, Inc. (EVIO) toward 2018 Goal of Opening 18 Cannabis Testing Labs
• IEG Holdings Corp. (IEGH) Capitalizes on Growing Consumer Lending Market with Unsecured Personal Loan Model

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$PVOTF Extracts Maximum Benefit from Cannabis Portfolio

April 6, 2018

• Forecasts predict $55.8 billion valuation for medical cannabis market by 2025
• Pivot Pharmaceuticals building portfolio of diverse tech for improving bioavailability of cannabinoid therapies
• Company’s leadership team builds on decades of experience in pharmaceutical arena

For nutrition-conscious consumers, scanning food product labels is a requisite part of any trip to the grocery store, but a recent study by the U.S. Department of Agriculture’s Agricultural Research Service (http://cnw.fm/i21Ex) found that the old maxim ‘what you see isn’t always what you get’ holds true when it comes to certain foods like nuts. Even though pistachios, for example, may have 161.9 calories per ounce, only 153.8 calories are utilized by the human body. The remaining five percent of those calories are given a pass by the body and not taken up, according to the research. Such information fuels the concept of bioavailability, or determining the portion of total nutrients that the body is able to extract for use in order to establish the real benefit a consumer derives from the product.

Bioavailability becomes a similarly important question in the consumption of medications, as health researchers and physicians work to determine how much real benefit a patient derives from a drug’s properties and how to improve the body’s use of them. For companies like Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT), enhancing a drug’s bioavailability is part of their bread and butter as they not only develop products designed to improve patients’ quality of life but try to ensure that these products deliver maximum benefit to the human body’s systems.

Pivot Pharmaceuticals’ patents in the field of cannabinoid use comprise a portfolio of landmark technologies that strive to increase bioavailability, drug release rates and product stability so that consumers can “confidently take correct and accurate doses to help meet their health and wellness needs.” Some patents maintain the company’s impetus in making cannabis available through powdered formulations that can be combined with products in the food and beverage market. Through subsidiary Thrudermic (http://cnw.fm/TUSd1), the company is invested in a transdermal lipid-based nano-dispersion technology that enhances skin absorption of cannabinoids, and the company’s water soluble, oral delivery product, PGS-N001, is designed to provide relief to cancer patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia by utilizing a bioavailability technology already demonstrated in Europe.

Market forecasts anticipate that the therapeutic product derivatives of cannabis will fuel a $55.8 billion market by 2025 as a growing number of governments legalize the oft-controversial drug’s use, according to a report issued last year by Grand View Research, Inc. (http://cnw.fm/0ybHh).

Pivot Pharmaceuticals’ innovations in the marketplace are driven by a leadership team that’s experienced in clinical, commercial, product development and financial management. CEO Patrick Frankham has over 20 years of experience in the pharmaceutical, biopharmaceutical and services industries, leading successful development programs in oncology, and he has been a founder, investor and board member of several health care ventures during the past 15 years.

“Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of bio-cannabis products,” Frankham stated in summarizing the company’s mission (http://cnw.fm/cS0Ct).

Board of Directors Chairman Ahmad Doroudian founded Merus Labs International Inc., and he has also filled executive positions for other pharmaceutical companies as part of his activities since becoming involved in early stage financing and management of private and publicly listed companies in the 1990s.

Dr. Wolfgang Renz, a business executive with expertise in medical innovation and cross-industry convergence, as well as a physician specializing in hepatology, serves on the board of directors, and accounting administrator Moira Ong serves as the company’s chief financial officer.

In 2017, Pivot’s Canadian leadership created a United States-based entity to take advantage of the increased legalization of the cannabis market in California and other North American locales, accelerating the monetization of the company’s Ready To Infuse Cannabis (“RTIC”) technology for products in the food and beverage industry. Pivot Naturals, LLC is led by President Pat Rolfes and Director of Research and Development Ross Franklin. Rolfes and Franklin led RTIC developer ERS Holdings LLC prior to the acquisition of that company and its patents by Pivot, and they are joined on the Pivot USA executive team by product formulation administrators Joseph Borovsky and Leonid Lurya, who were the scientific technology executives on the Thrudermic team upon its acquisition.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

• Strong Leadership Team Guides EVIO, Inc. (EVIO) toward 2018 Goal of Opening 18 Cannabis Testing Labs
• Earth Science Tech, Inc. (ETST) Accelerates the Development and Commercialization of Products
• EVIO, Inc. (EVIO) Puts Cannabis Quality and Safety to the Test

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$DTRM President, CEO and Director Patrick Stakenas Featured in Nationwide Media

Business Rockstars, the Largest Platform for Entrepreneurs, Highlights the Advice and Accomplishments of Determine’s Source-to-Pay Visionary in Markets Across the US

CARMEL, Ind., April 05, 2018 – Determine, Inc. (NASDAQ:DTRM), a pioneering leader in global Source to Pay and Enterprise Contract Lifecycle Management (ECLM) Cloud Platform solutions, announced today that President, Chief Executive Officer and Director Patrick Stakenas will be featured on Business Rockstars in coast-to-coast distribution beginning the week of April 9.

Mr. Stakenas, who in addition to spearheading the creation of Determine by combining industry leaders Iasta, b-pack and Selectica, has amassed extensive career accomplishments as an entrepreneur, business owner and industry executive. His segment on Business Rockstars offers real-world advice for aspiring entrepreneurs on how to make critical decisions that lead to success.

Business Rockstars brings together the biggest and most accomplished CEO’s, entrepreneurs, celebrities, small business owners, innovators, and disruptors, providing a daily television, radio, and online show that reaches millions of people around the world. Mr. Stakenas’ interview and segment will run across the entire media platform, including 125 US airports, 150 radio markets, leading hotels and over 43 million households.

About Business Rockstars
“Business Rockstars” is the biggest entrepreneur platform on the planet. It produces video and audio content by award winning content creators and influencers. Business Rockstars is connecting and growing a community of “wantrepreneurs” and entrepreneurs on television, radio, podcast & social media. “Business Rockstars” shows are produced from their Burbank studios, with remote video broadcast facilities in New York and San Francisco, through strategic partner, NASDAQ Private Market. Business Rockstars can be seen in 43 million TV households, 150 Radio markets, Dash Radio, all major podcast platforms, with over 1 million social media followers. Business Rockstars digital content can be seen on Entrepreneur, Yahoo Finance, MSN, businessrockstars.com.

Supporting Resources

Determine Blog

Determine on LinkedIn

Determine on Twitter

Determine Resources

About Determine, Inc.
Determine, Inc. (NASDAQ:DTRM) is a leading global provider of SaaS Source-to-Pay and Enterprise Contract Lifecycle Management (ECLM) solutions. The Determine Cloud Platform provides procurement, legal and finance professionals analytics of their supplier, contract and financial performance. Our technologies empower customers to drive new revenue, identify savings, improve compliance and mitigate risk.

The Determine Cloud Platform seamlessly integrates with major ERP or third-party systems such as SAP, Oracle, Sage, QAD and Microsoft. Modular solutions can be configured to add more as needed to provide additional value beyond spend management. Our unified master database and business process approach empower users at every level to make more informed and smarter decisions.

For more information, please visit: www.determine.com.

Contact

Media Relations:
Mike Mitchell
Determine, Inc.
+1.650.532.1590
pr@determine.com

$VSQTF NetworkNewsAudio Announces Audio Press Release on Virtual Reality and Blockchain

New York, New York–(April 5, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “This Could Be the Year Virtual Reality Conquers the Tech World,” featuring Victory Square Technologies, Inc. (CSE: VST) (OTC Pink: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8).

To hear the NetworkNewsAudio version, visit http://nnw.fm/ZwhR1

To read the original editorial, visit http://nnw.fm/mI9Md

In the realm of advertising, the promise of VR-based marketing like the Chrysler campaign and its potential integration with blockchain — an area in which Victory Square Technologies (OTC: VSQTF) (CSE: VST) is already an expert in — have unreal potential. The company has already invested and incubated numerous businesses in the blockchain tech space, but it also has an existing VR project in the fast-growing VR gaming industry, so it’s no stranger to either technology. Victory Square chose Flo Digital, because it’s currently building out the first-ever blockchain-based VR advertising technology platform.

According to experts, a VR-blockchain combination could spark a digital advertising revolution by solving many common problems encountered in this space such as data transparency, ad fraud and misuse of money spent on advertisements. A possible solution is for platforms to record and measure people’s interaction with VR ads and make payments to content owners accordingly. The whole process could be done on blockchain’s secure, accurate and transparent curation of data, saving money for all involved.

About Victory Square Technologies Inc.

Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, visit www.VictorySquare.com.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) is another NetworkNewsWire (NNW) Solution that can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$ETST Accelerates the Development and Commercialization of Products

April 5, 2018

• Company announces its membership in Défi Montréal, Canada’s largest business acceleration program
• Partnership with Laboratories BNK Canada, Inc. allows ETST to commercialize its new testing services more quickly
• Strategic acquisition aimed at improving access to funding for development of treatments for various diseases

Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company that operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals and medical devices, is taking active measures to accelerate its development and growth. On March 22, 2018, ETST announced its membership in the 16th cohort of Défi Montréal, the largest innovative business acceleration program in Quebec. Martin Duchaîne, founder of Défi Montréal, has advised or assisted over 900 entrepreneurs in his 20-year career. This new membership is expected to accelerate the development and commercialization of new ETST products in Canada and overseas (http://cnw.fm/J5fFa).

Through ETST’s connection with Défi Montréal, key individuals have already been brought on board to advance the acceleration of operations. In January 2018, ETST announced a deal with Laboratories BNK Canada, Inc. for clinical studies related to the MSN-2 medical device. The MSN-2 is a home kit designed for the detection of sexually transmitted infections (STIs) from a self-obtained gynecological specimen. MSN-2 has been confirmed through studies to detect chlamydia. The company is working to validate similar results for gonorrhea. Testing for trichomoniasis, as well as different serotypes of the human papillomavirus (HPV), are expected to be added in the near future. Partnering with Laboratories BNK offers ETST an accelerated plan of development for more products while cutting costs and, ideally, treating more patients. This arrangement gives ETST the means to accelerate the commercialization of its new testing services while it works toward its ultimate goal of halting the spread of STIs.

ETST holds three wholly owned subsidiaries, including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and KannaBidioid Inc. In 2017, ETST acquired Canna Inno Laboratories Inc. as a strategic move that gave ETST access to government grants. The first of these grants was awarded from the Government of Québec for innovation in the pharmaceutical industry and will support the pre-launch process of ETST’s three CBD-based products that aim to prevent common causes of cancer and help reduce occurrence rates.

ETST strives to discover solutions for conditions with no current effective treatment, targeting diseases for which the benefits of CBD have been demonstrated by researchers worldwide. The move to accelerate the development and commercialization of these products is an effort to improve treatments for different diseases on a global scale.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• EVIO, Inc. (EVIO) Puts Cannabis Quality and Safety to the Test
• Xanthic Biopharma Inc. Establishing a New Paradigm in Cannabinoid Delivery
• ChineseInvestors.com, Inc. (CIIX) to Debut ‘Bitcoin Big Winner’ Program on Phoenix North America Chinese Channel

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$NETE Subsidiary Launches New Same-Day Funding Service

Contact:
Net Element, Inc.
media@netelement.com
+1 (786) 923-0502

$TENX Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan

MORRISVILLE, N.C.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).

The FDA agreed that the new Phase 2 clinical protocol can be submitted under the existing IND, and supported the study design and endpoints for demonstrating proof-of-concept in PH-HFpEF patients.

“We are very pleased with the outcome of the pre IND meeting,” said Michael Jebsen, Interim CEO of Tenax. “The initial pathway to move forward with the development of levosimendan in PH-HFpEF has been clarified and confirmed. We will finalize our Phase 2 clinical trial protocol for IND submission and continue preparations for a late June or July start of the trial.”

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on licensing, development, and commercialization of drugs that address conditions with high unmet medical need. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension. The Company owns the North American rights to develop and commercialize levosimendan and is finalizing preparations to begin their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) early in the second half of 2018. For more information, visit www.tenaxthera.com.

About Levosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired the North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the Company’s control that could lead to delays in the clinical study, delays in new product introductions and customer acceptance of these new products, matters beyond the Company’s control that could impact the Company’s continued compliance with Nasdaq listing requirements, and other risks and uncertainties as described in the Company’s filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on April 2, 2018 and its other filings with the SEC. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

$VSQTF NetworkNewsWire Publication on Cutting-Edge and Immersive VR/AR Experiences

NetworkNewsWire Editorial Coverage: Ever since it was introduced five years ago, virtual reality (VR) technology has been underwhelming due to the lack of content and the exuberant costs of headsets like Oculus. But this year, the VR market could grow by 25 percent, according to the Consumer Technology Association, thanks to new products announced by Google and others in the tech world. VR enthusiasts are also predicting that Steven Spielberg’s newest film, which depicts a futuristic VR universe, could push the technology into mainstream. However, the biggest boost to VR technology potentially comes from the integration of blockchain technology. This is where blockchain companies could bring the true potential of VR into life. Companies at the forefront of this technology include Victory Square Technologies, Inc. (OTC: VSQTF) (CSE: VST) (VSQTF Profile), 360 Blockchain, Inc. (CSE: CODE), Hashchain Technology, Inc. (TSX-V: KASH), BTCS, Inc. (OTC: BTCS), and Marathon Patent Group, Inc. (NASDAQ: MARA).

At the recent Game Developers Conference in San Francisco, tech giants such as Facebook, Sony and Google all advocated for VR technologies. According to Forbes (http://nnw.fm/RyP8D), the biggest takeaway from this conference is that there was less talk about experimental VR and more about commercial VR, such as in advertising. Clearly, the VR market is on a trajectory into a new era. Based on reports from Business Insider, it is estimated that the VR market will grow from $2 billion to $27 billion between 2016 and 2022 (http://nnw.fm/Fc44G).

Recognizing that VR could finally become a mainstream consumer technology, Victory Square Technologies landed a arrangement last week to acquire 49% (percent) of Flo Digital Inc., a VR advertising experience platform with access to over 200 million monthly viewers across North America. Flo Digital’s VR network already spans several platforms, including HTC VIVE, Google Cardboard, Google Daydream, IOS, Android and Web VR. One of its latest VR projects was a collaboration with Chrysler Canada, which allowed users to virtually test drive the all-new Challenger.

Blockchain Unlocks Unreal Potential in Advertising

In the realm of advertising, the promise of VR-based marketing like the Chrysler campaign and its potential integration with blockchain — an area in which Victory Square Technologies (OTC: VSQTF) (CSE: VST) is already an expert in — have unreal potential. The company has already invested and incubated numerous businesses in the blockchain tech space, but it also has an existing VR project in the fast-growing VR gaming industry, so it’s no stranger to either technology. Victory Square chose Flo Digital, because it’s currently building out the first-ever blockchain-based VR advertising technology platform.

According to experts, a VR-blockchain combination could spark a digital advertising revolution by solving many common problems encountered in this space such as data transparency, ad fraud and misuse of money spent on advertisements. A possible solution is for platforms to record and measure people’s interaction with VR ads and make payments to content owners accordingly. The whole process could be done on blockchain’s secure, accurate and transparent curation of data, saving money for all involved.

Procter & Gamble made headlines last year for threatening to pull $2.4 billion in ad spending because of ongoing ad fraud and transparency issues, even calling out its partner Facebook.

P&G’s chief brand officer Marc Pritchard stated at the time: “There is, we believe, at least 20 percent to 30 percent of waste in the media supply chain because of lack of “viewability,” non-transparent contracts, non-transparent measurement of inputs, fraud, and now even your ads showing up in unsafe places.” The solution to this is a combination of VR (better user experience) and blockchain (transparency).

Google is already encouraging developers to work with a VR prototype to replace traditional advertising, and so have Apple and Microsoft. This presents a big opportunity for companies such as Victory Square Technologies (OTC: VSQTF) (CSE: VST) with strong footprints in both VR and blockchain to make a technological breakthrough with its potentially first-of-its-kind Flo Digital platform.

Commenting on its newest VR-blockchain acquisition, Shafin Diamond Tejani, Victory Square CEO, said: “Flo Digital has a proven track record of providing cutting-edge and immersive VR/AR experiences to leading brands that include Chrysler Canada, Warner Bros. and Rogers Wireless, to name a few. It is this calibre of customers and execution that makes the entire team at Victory Square eager to work with Flo Digital on their next stage of growth.

“This represents another investment in the VR/AR industry and further illustrates our thesis that blockchain technology will disrupt the existing landscape in ad tech and ultimately change the way brands will connect with their customers,” Tejani added.

Other Players in the Blockchain Space

360 Blockchain (CSE: CODE) is building an all-round blockchain ecosystem that includes cryptocurrencies, smart contracts and data management. In December, the company announced its intention to invest in Arcology, a platform that uses machine learning and pattern recognition technology to create hierarchical blockchain structures. Recently, 360 Blockchain completed its acquisition of a 60 percent stake in SV CryptoLab, a Silicon Valley-based crypto facility.

Hashchain Technology (TSX-V: KASH) is the first public cryptocurrency mining company to file a final prospectus in Canada supporting highly scalable and flexible mining operations across all major cryptocurrencies. Last month, the company completed the acquisition of NODE40 LLC, which comprises a team of experienced blockchain experts and software engineers.

BTCS (OTC: BTCS) is one of the first public companies in the United States to be involved with digital assets and blockchain technologies. The company plans to create a portfolio of digital assets including Bitcoin and other “protocol tokens.” It has an agreement in place to merge with Blockchain Global Ltd., an Australian blockchain company.

Marathon (NASDAQ: MARA) is focused on acquiring patents and patent rights from individual owners and Fortune 500 companies. The company monetizes its portfolio by entering licensing deals. Earlier this year, Marathon entered a purchase agreement to acquire four patents related to the transmission and exchange of cryptocurrencies between buyers and sellers.

Spielberg’s New Film Could Ignite a VR Tech Fever

Although VR technology is still at an infancy stage, it is also about to receive a big lift in the real world thanks to Steven Spielberg’s highly anticipated ”Ready Player One” — centered around a utopian VR future — hitting theatres on March 29. Like previous Hollywood releases that have produced remarkable marketing results (i.e., The Blues Brothers was credited for boosting sunglasses sales in the 1980s), this film will give the audience a grandiose visualization of the infinite possibilities created by VR technology, which transcend real-life experiences, potentially helping to ignite a VR fever that already seems to be gaining traction.

This signals an ideal time for companies to delve deeper into this tech space, much like Victory Square Technologies has just done with the Flo Digital acquisition. Now that Spielberg’s next big release is set to become a big marketing campaign for VR, the next step is to realize the technology’s true potential in advertising through the help of blockchain.

Imagine a platform that charges advertisers solely on the amount of time consumers were immersed in the VR content and rewards content producers accordingly, with all transactions safely recorded on blockchain. A VR-blockchain integration could finally eliminate the 20 to 30 percent waste resulting from inefficient advertising, and Victory Square Technologies could be the one to bring that kind of platform into life.

For more information on Victory Square Technologies Inc. (OTC:VSQTF) (CSE:VST), please visit StreetSignals.com for a free research report.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

$PVOTF Posts Product Development Update

VANCOUVER, April 4, 2018 – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) is pleased to provide a corporate update on the advancements of its industry leading bio-cannabis product pipeline. As previously announced, a 1% CBD Oral Micelle Solution developed in Germany is ready-to-market and development of two topical creams using the Company’s patented formulation and delivery systems is now complete.

In light of this development, the Company is anticipating that it will have several products available for sale in Canada on the date legalization officially begins. Pivot also projects to begin sales in California as of Q3 2018, including the launch of its proprietary line of “Ready-to-Infuse-Cannabis” (“RTIC”) natural health products. The sale of bulk powder, stick packs and capsules is expected to drive significant revenue.

The patents secured to date provide a significant opportunity for Pivot to create proprietary products that are unmatched in quality by current licensed producers and product distributors. The Company’s Intellectual Property portfolio covers several key patent areas which have previously demonstrated their ability to deliver pharmaceutical grade products in clinical trials. Pivot will now manufacture and commercialize its pipeline in anticipation of the legalization of cannabis in Canada as well as internationally, where regulations permit.

Pivot’s differentiated business model has entailed acquiring disruptive drug formulation and delivery technologies and then to develop dosable and reproducible bio-cannabis products for consumers. Pivot’s patent  protected products will enable the Company to secure sales free from competitors claiming similar activities.  According to the World Intellectual Property Organization (WIPO) pursuing a patent strategy allows Pivot to have:

• Exclusive rights
• Strong market position
• Higher returns on investment
• Opportunities to license or sell Inventions
• Have a strong negotiation position with companies that may infringe

Dr. Joseph Borovsky, Pivot’s Vice President, Formulations, indicates that “our development team in Israel has now completed key development milestones with our nanoparticulate transdermal technology product as well as with our BiPhasix topical product.  These two lead product candidates will complete final testing and we will announce our scale-up and marketing strategy in the coming months.”

“Canadian Licensed Producers have invested extensively in dried flower and oil production capacity but have not focused on downstream sustainable quality products made from cannabis. Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of  bio-cannabis products,” said Dr. Patrick Frankham, Pivot’s CEO.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, project, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc. or Pivot Green Stream Health Solutions Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

$ETST Subsidiary Demonstrates Innovation in the Pharmaceutical Industry

March 13, 2018

• Received grant from Government of Québec through Canno Inno Laboratories subsidiary
• Canna Inno Laboratories enhances collaboration between the company’s resources in Canada and the U.S. while providing access to grants
• Sound scientific research and transparent studies

Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company focused on cannabis, industrial hemp and cannabinoid research and development for nutraceuticals, pharmaceuticals and medical devices, announced last week that its subsidiary, Canna Inno Laboratories Inc., has received a grant from the Government of Québec for innovation in the pharmaceutical industry. ETST plans to apply for additional funding under Canada’s Scientific Research and Experimental Development Tax Credit program (http://nnw.fm/YN2cr).

Earth Science Tech formed Canna Inno Laboratories, Inc. in 2017. Strategically headquartered in Montreal, Quebec, it allows Earth Science Tech access to Canadian government and private grants offered to companies for innovation in the pharmaceutical industry. The awarded grant will support the pre-launch process of Earth Science’s three CBD-based products. These nutraceutical products aim to prevent common causes of cancer and help reduce occurrence rates. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Once complete and patent pending, these high-grade hemp CBD oil products will be commercialized as nutraceuticals and provide alternative natural treatment solutions.

Through the in vitro study with the University of Central Oklahoma and DV Biologics, ETST has provided results that confirm the positive effect of its CBD on breast cancer, immune cell function and human brain cells. The goal of ETST is to discover solutions for conditions that currently have no effective treatment, targeting diseases in which the benefits of CBD have already been demonstrated by researchers worldwide. ETST seeks to increase the effectiveness of cannabinoids and/or CBD and thereby improve treatments for different diseases. The company focuses on providing sound scientific research and transparency on the progression of studies done on its highest quality and purity, full spectrum high-grade hemp CBD products.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

• Xanthic Biopharma Inc. Establishing a New Paradigm in Cannabinoid Delivery
• Petroteq Energy Inc.’s (TSX.V: PQE) (OTCQX: PQEFF) Proprietary Oil Extraction Technology Favors the Environment
• OTC Markets Group Cracks Down on Manipulative and Misleading Stock Promotion

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX to Present at The MicroCap Conference on April 9th and 10th in New York City

SAN GABRIEL, California, April 4, 2018 —

ChineseInvestors.com Inc. (OTCQB: CIIX)(“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, announces that will be presenting at this year’s MicroCap Conference on April 9th and 10th in New York City.

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. Conference attendees are provided the opportunity to interact with management at some of the most attractive small companies, to learn from the various expert panels, and to mingle with other microcap investors.

At the conference, ChineseInvestors.com, Inc.’s CEO Warren Wang will present information regarding the Company’s business updates including its developing cryptocurrency business which focuses on three areas: Cryptocurrency Media & Education Services; Cryptocurrency ATMs and Mining.

In November 2017 the Company launched http://www.newcoins168.com , a premier Chinese cryptocurrency and blockchain technology information and education platform providing straightforward explanation of cryptocurrency basics, trading guidelines, real-time market commentary and analysis regarding mining, blockchain technology, industry hotspots, sec-tor-related stock trends and ETFs, and other strategies and opportunities to capitalize on this growing market.

The Company also provides a Bitcoin ATMs with on-site customer service representatives providing instruction in both Chinese and English. In addition, the Company is exploring investments in Cryptocurrency Mining with its recent purchase of ASIC (Application Specific Integrated Circuit) machines used to mine SHA-256 or Scrypt mining algorithms to earn cryptocurrencies such as Bitcoin and Litecoin.

“We look forward to providing attendees with information regarding the Company’s cryptocurrency business and welcome this opportunity to network with leading micro-cap and small-cap professionals,” says CIIX founder and CEO Warren Wang.

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Visit and register https://www.newcoins168.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776
Investor Relations:
Alan Klitenic
+1-214-636-2548
Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

$BPTH Interim Data from Phase 2 Clinical of Prexigebersen in AML

 Prexigebersen plus LDAC was well-tolerated and showed early anti-leukemic activity in nearly 50% of evaluable AML patients treated to date

Planned protocol amendments may provide for potential approvals in the U.S. and Europe of two prexigerbesen combination treatments

HOUSTON, April 03, 2018 — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces that interim data from its Phase 2 study of prexigebersen in combination with low-dose cytarabine (LDAC) (BP1001-201) for the treatment of acute myeloid leukemia (AML) has demonstrated that the combination therapy continues to be well-tolerated and has shown early anti-leukemic activity in nearly 50% of evaluable AML patients including four patients with complete remission and four with stable disease to date in this study.

The open-label Phase 2 study is evaluating the efficacy and safety of prexigebersen in conjunction with LDAC, a therapeutic regimen well established in treatment of AML patients who cannot or elect not to be treated with more intensive chemotherapy.  The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy than what would be expected with LDAC alone in this de novo patient population.  The study had a pre-determined decision point at 19 evaluable patients in which the study would be terminated if less than 5 patients responded and the study would be expanded to 54 patients if five or more patients responded.

The interim analysis was performed on 17 evaluable patients instead of 19, since criteria to move to the next steps in the study had been met.  Of the 17 evaluable patients, there were four patients who achieved complete responses, one patient who achieved a morphologic leukemia free state, two patients who had significantly reduced bone marrow blasts and four patients with stable disease.  In total, 47% of the evaluable patients showed some form of response, including stable disease, to the combination treatment. The average age of patients in the study was 73.5 years old.

Based on the recommendations of the principal investigators of the study, the Company is  amending the protocol to change the dosing schedule to that used in the Phase 1b study in relapsed and refractory AML patients in which a higher dose of prexigerbesen was administered prior to LDAC treatment starting at day 10 versus LDAC treatment starting on day four as was the case in the BP1001-201 study to date.  In addition, the investigators endorse the inclusion of a decitabine cohort based on relatively new and positive data with this compound.

“We are very pleased with these encouraging interim data as they demonstrate the potential for the combination of prexigerbesen and LDAC to effectively treat these de novo AML patients.  These early results are encouraging when you consider that the complete response rate in elderly AML patients greater than 65 years of age on LDAC alone have been estimated (Lin Journal of Clinical Oncology Abstract) to be only 10%¹,” noted Peter H. Nielsen, chief executive officer of Bio-Path.  “We look forward to advancing the planned protocol amendments as we expect they will provide even better results for these patients suffering with AML.  If successful, it will provide for approvals in the U.S. and Europe for both combination therapies.”

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company’s website at http://www.biopathholdings.com.

References
¹ Lin, T. (2016). Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. Journal of Clinical Oncology. 34(15). doi: 10.1200/JCO.2016.34.15_suppl.7007

Contact Information:

Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

$MYND Completes $2.1 Million Dollar Private Placement by Company Insiders

MISSION VIEJO, Calif., April 03, 2018 — MYnd Analytics, Inc. (NASDAQ:MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that it completed a private placement for gross proceeds of $2.1 million (the “Financing”) on March 29, 2018.  The Company sold an aggregate of 1,050,000 units for $2.00 per unit (the “Units”), each consisting of one share of newly-designated Series A Preferred Stock (the “Series A Preferred Stock”) and one Warrant (the “Warrants”) to purchase one share of Common Stock (“Common Stock”) for $2.34 per share to three affiliates of the Company. The closing price per share of the Common Stock on the Nasdaq Stock Market on March 29, 2018 was $1.19 per share.

Shares of the Company’s Series A Preferred Stock will be entitled to receive cash dividends at the rate of five percent (5.00%) of the Original Series A Issue Price per annum. The Warrants will be exercisable for a period of five years for an exercise price of $2.34. The exercise price is subject to adjustment for stock splits, stock dividends, combinations or similar events. The Warrants may not be exercised on a cashless basis.

In connection with the Financing, MYND also entered into a registration rights agreement (the “Registration Rights Agreement”) with the investors, requiring MYND to register the resale of the shares of Common Stock underlying the preferred stock and the Warrants. The Company expects to use the proceeds of the Financing for general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

A complete and detailed description of the Agreement and related registration rights agreement is set forth in MYND’ Current Report on Form 8-K, filed today with the Securities & Exchange Commission.

About MYnd Analytics

MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 39,000 outcomes for over 11,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.

MYnd also operates its wholly owned subsidiarity Arcadian Telepsychiatry Services, LLC which manages a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Arcadian utilizes patient engagement and re-engagement strategies so that care is effectively completed, helping to comfortably move inpatient care to outpatient, assisting patients in readjusting to their life routine, as well as reducing wait times for mental health treatment. Arcadian’s customer base includes major health plans, health systems, and community-based organizations.

Forward-looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as MYnd’s ability to successfully expand into various market channels, the ability of its products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses and MYnd’s ability to expand globally in areas where there is an opportunity to improve treatment in mental health, to continue to protect and enforce its patents, as well as those risks and uncertainties set forth in MYnd’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein. 

To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.

Contact:

Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: mynd@crescendo-ir.com

$CASI To Present At The H.C. Wainwright Global Life Sciences Conference

ROCKVILLE, Md., April 3, 2018 — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces it will present at the H.C. Wainwright Global Life Sciences Conference, April 8 – 10, 2018 in Monte Carlo, Monaco.

Presentation details are below:

Event:  H.C. Wainwright Global Life Sciences Conference
Date:  Tuesday, April 10, 2018
Time:  4:15 – 4:40 p.m. Local Time
Presenter: Ken K. Ren, Ph.D., Chief Executive Officer
Presentation Room:  Salon Atlantic-W (2^nd Floor), Le Meridien Beach Plaza Hotel, Monte Carlo

A copy of the presentation materials will be made available directly through the Investor Relations section of the company’s website, www.casipharmaceuticals.com, on April 10, 2018.

About CASI Pharmaceuticals, Inc.

CASI is a U.S. based biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients. CASI’s product pipeline features (1) EVOMELA^®, MARQIBO^®, and ZEVALIN^®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory process for market approval in China, (2) an acquired portfolio of 25 FDA-approved abbreviated new drug applications (ANDAs), one ANDA that was tentatively approved and three ANDAs that are pending FDA approval, from which CASI will prioritize a select subset for product registration and commercialization in China, (3) our proprietary drug candidate, ENMD-2076, currently in Phase 2 clinical development, and (4) proprietary early-stage candidates in immuno-oncology preclinical development.  CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China.  More information on CASI is available at www.casipharmaceuticals.com and in the Company’s filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.  Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of executing our business strategy in China; the risk that we will not be able to effectively select, register and commercialize products from our recently acquired portfolio of ANDAs; our inability to predict when or if our product candidates will be approved for marketing by CFDA authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

EVOMELA^®, MARQIBO^®, and ZEVALIN^® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.

$VSQTF This Could Be the Year Virtual Reality Conquers the Tech World

April 3, 2018

NetworkNewsWire Editorial Coverage: Ever since it was introduced five years ago, virtual reality (VR) technology has been underwhelming due to the lack of content and the exuberant costs of headsets like Oculus. But this year, the VR market could grow by 25 percent, according to the Consumer Technology Association, thanks to new products announced by Google and others in the tech world. VR enthusiasts are also predicting that Steven Spielberg’s newest film, which depicts a futuristic VR universe, could push the technology into mainstream. However, the biggest boost to VR technology potentially comes from the integration of blockchain technology. This is where blockchain companies could bring the true potential of VR into life. Companies at the forefront of this technology include Victory Square Technologies, Inc. (OTC: VSQTF) (CSE: VST) (VSQTF Profile), 360 Blockchain, Inc. (CSE: CODE), Hashchain Technology, Inc. (TSX-V: KASH), BTCS, Inc. (OTC: BTCS), and Marathon Patent Group, Inc. (NASDAQ: MARA).

At the recent Game Developers Conference in San Francisco, tech giants such as Facebook, Sony and Google all advocated for VR technologies. According to Forbes (http://nnw.fm/RyP8D), the biggest takeaway from this conference is that there was less talk about experimental VR and more about commercial VR, such as in advertising. Clearly, the VR market is on a trajectory into a new era. Based on reports from Business Insider, it is estimated that the VR market will grow from $2 billion to $27 billion between 2016 and 2022 (http://nnw.fm/Fc44G).

Recognizing that VR could finally become a mainstream consumer technology, Victory Square Technologies landed a arrangement last week to acquire 49% (percent) of Flo Digital Inc., a VR advertising experience platform with access to over 200 million monthly viewers across North America. Flo Digital’s VR network already spans several platforms, including HTC VIVE, Google Cardboard, Google Daydream, IOS, Android and Web VR. One of its latest VR projects was a collaboration with Chrysler Canada, which allowed users to virtually test drive the all-new Challenger.

Blockchain Unlocks Unreal Potential in Advertising

In the realm of advertising, the promise of VR-based marketing like the Chrysler campaign and its potential integration with blockchain — an area in which Victory Square Technologies (OTC: VSQTF) (CSE: VST) is already an expert in — have unreal potential. The company has already invested and incubated numerous businesses in the blockchain tech space, but it also has an existing VR project in the fast-growing VR gaming industry, so it’s no stranger to either technology. Victory Square chose Flo Digital, because it’s currently building out the first-ever blockchain-based VR advertising technology platform.

According to experts, a VR-blockchain combination could spark a digital advertising revolution by solving many common problems encountered in this space such as data transparency, ad fraud and misuse of money spent on advertisements. A possible solution is for platforms to record and measure people’s interaction with VR ads and make payments to content owners accordingly. The whole process could be done on blockchain’s secure, accurate and transparent curation of data, saving money for all involved.

Procter & Gamble made headlines last year for threatening to pull $2.4 billion in ad spending because of ongoing ad fraud and transparency issues, even calling out its partner Facebook.

P&G’s chief brand officer Marc Pritchard stated at the time: “There is, we believe, at least 20 percent to 30 percent of waste in the media supply chain because of lack of “viewability,” non-transparent contracts, non-transparent measurement of inputs, fraud, and now even your ads showing up in unsafe places.” The solution to this is a combination of VR (better user experience) and blockchain (transparency).

Google is already encouraging developers to work with a VR prototype to replace traditional advertising, and so have Apple and Microsoft. This presents a big opportunity for companies such as Victory Square Technologies (OTC: VSQTF) (CSE: VST) with strong footprints in both VR and blockchain to make a technological breakthrough with its potentially first-of-its-kind Flo Digital platform.

Commenting on its newest VR-blockchain acquisition, Shafin Diamond Tejani, Victory Square CEO, said: “Flo Digital has a proven track record of providing cutting-edge and immersive VR/AR experiences to leading brands that include Chrysler Canada, Warner Bros. and Rogers Wireless, to name a few. It is this calibre of customers and execution that makes the entire team at Victory Square eager to work with Flo Digital on their next stage of growth.

“This represents another investment in the VR/AR industry and further illustrates our thesis that blockchain technology will disrupt the existing landscape in ad tech and ultimately change the way brands will connect with their customers,” Tejani added.

Other Players in the Blockchain Space

360 Blockchain (CSE: CODE) is building an all-round blockchain ecosystem that includes cryptocurrencies, smart contracts and data management. In December, the company announced its intention to invest in Arcology, a platform that uses machine learning and pattern recognition technology to create hierarchical blockchain structures. Recently, 360 Blockchain completed its acquisition of a 60 percent stake in SV CryptoLab, a Silicon Valley-based crypto facility.

Hashchain Technology (TSX-V: KASH) is the first public cryptocurrency mining company to file a final prospectus in Canada supporting highly scalable and flexible mining operations across all major cryptocurrencies. Last month, the company completed the acquisition of NODE40 LLC, which comprises a team of experienced blockchain experts and software engineers.

BTCS (OTC: BTCS) is one of the first public companies in the United States to be involved with digital assets and blockchain technologies. The company plans to create a portfolio of digital assets including Bitcoin and other “protocol tokens.” It has an agreement in place to merge with Blockchain Global Ltd., an Australian blockchain company.

Marathon (NASDAQ: MARA) is focused on acquiring patents and patent rights from individual owners and Fortune 500 companies. The company monetizes its portfolio by entering licensing deals. Earlier this year, Marathon entered a purchase agreement to acquire four patents related to the transmission and exchange of cryptocurrencies between buyers and sellers.

Spielberg’s New Film Could Ignite a VR Tech Fever

Although VR technology is still at an infancy stage, it is also about to receive a big lift in the real world thanks to Steven Spielberg’s highly anticipated ”Ready Player One” — centered around a utopian VR future — hitting theatres on March 29. Like previous Hollywood releases that have produced remarkable marketing results (i.e., The Blues Brothers was credited for boosting sunglasses sales in the 1980s), this film will give the audience a grandiose visualization of the infinite possibilities created by VR technology, which transcend real-life experiences, potentially helping to ignite a VR fever that already seems to be gaining traction.

This signals an ideal time for companies to delve deeper into this tech space, much like Victory Square Technologies has just done with the Flo Digital acquisition. Now that Spielberg’s next big release is set to become a big marketing campaign for VR, the next step is to realize the technology’s true potential in advertising through the help of blockchain.

Imagine a platform that charges advertisers solely on the amount of time consumers were immersed in the VR content and rewards content producers accordingly, with all transactions safely recorded on blockchain. A VR-blockchain integration could finally eliminate the 20 to 30 percent waste resulting from inefficient advertising, and Victory Square Technologies could be the one to bring that kind of platform into life.

For more information on Victory Square Technologies Inc. (OTC:VSQTF) (CSE:VST), please visit StreetSignals.com for a free research report.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

$PBIO Fourth Quarter, Fiscal Year 2017 Financial Results, Business Update

Instrument and Consumable Sales Show Continued Double-Digit Growth in Q4 and FY2017; Total Annual Revenue Exceeds $2 Million for First Time

2017 New Product Releases, CE Marking, GMP Compliance, Acquisition of BaroFold Assets, Initial UST Patents & Significant Expansion of Sales & Marketing Capabilities Expected to Fuel Growth in FY2018

Investor Conference Call Scheduled for Tuesday, April 3, 2018 at 4:30 PM EDT

SOUTH EASTON, MA / April 3, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2017, provided a business update, and offered limited guidance for FY2018.

Financial Results: Q4 2017 vs. Q4 2016

Products and services revenue was $455,767 for the fourth quarter of 2017 compared to $365,262 for the same quarter of 2016, a 25% increase. Sales of instruments increased to $317,498 in Q4 2017 compared to $204,460 in Q4 2016, an increase of 55%. Sales of consumables were $60,108 for the fourth quarter of 2017 compared to $50,054 for the same period in 2016, a 20% increase. Grant revenue in Q4 2017 was $46,941 compared to $54,449 in Q4 2016.

Total revenue for the fourth quarter ended December 31, 2017 was $502,708 compared to $419,711 for the same period in 2016, a 20% increase. This increase was primarily due to our double-digit growth in products and services.

Operating loss for Q4 2017 was $1,318,384 compared to $1,177,205 for the same period in 2016. This increase in operating loss was primarily due to increases in sales and marketing expenses related to the expansion of our field sales team from one to five individuals during FY2017, as well as to an inventory allowance in FY2017 of $159,600.

Loss per common share – basic – was $2.37 for Q4 2017 compared to income per common share of $3.13 for the same period in 2016. Loss per common share – diluted – was $2.37 for Q4 2017 compared to loss per common share of $0.64 for the same period in 2016.

Financial Results: FY2017 vs. FY2016

Products and services revenue was $2,065,891 for the year ended December 31, 2017 compared with $1,794,749 for the year ended December 31, 2016, a 15% increase. Sales of instruments increased to $1,459,326 for FY2017 compared to $1,205,520 for FY2016, an increase of 21%. Sales of consumables were $260,331 for the year ended December 31, 2017 compared to $199,873 for the same period in 2016, an increase of $60,458 or 30%. Grant revenue for fiscal year 2017 was $174,607 compared to $181,738 for the 2016 fiscal year.

Total revenue for FY2017 was $2,240,498 compared to $1,976,487 for FY2016, a 13% increase. This increase was primarily due to our double-digit growth in products and services.

Operating loss for FY2017 was $4,647,048 compared to $3,735,653 for FY2016. This increase was primarily due to increases in sales and marketing expenses related to the build-out of a field sales force, an inventory allowance of $159,600, and the one-time administrative credits in the prior year, off-set to a certain extent by increases in total revenue.

Loss per common share – basic and diluted – was $9.62 for FY2017 and $2.97 for the 2016 fiscal year.

Operational & Technical Highlights: FY2017

• A significant software upgrade for our flagship Barocycler 2320EXTREME has brought our next-generation PCT-based instrument to GMP and GLP compliance, which in turn should open many new doors in the biopharmaceutical manufacturing and drug discovery & development areas of the very large life sciences field.

• The acquisition of all assets of BaroFold Corporation combines BaroFold’s patented high-pressure protein refolding technology (PreEMT) with PBI’s leadership in high-pressure instrumentation and worldwide market access, which will allow PBI entry into the Biologics Contract Research Services Sector.

• Professor Tiannan Guo’s laboratory at the world famous Westlake Institute for Advanced Study was named PBI’s first Center of Excellence in China, which we believe should support an aggressive marketing and sales strategy in China, which in turn could drive significant expansion in China and the rest of Asia.

• We believe our strategic collaboration with Phasex Corporation will allow us to address broad markets for stable, water-soluble nanoemulsions. We expect the combination of our recently patented Ultra Shear Technology (UST) with Phasex’s Supercritical Fluid processing methods will enable development of stable, water-soluble nanoemulsions, including CBD-enriched plant oil.

• We were issued the first two patents on our widely-applicable, high pressure-based Ultra Shear Technology. We believe that UST can be used to create or improve a broad range of medical, consumer, and industrial products through the preparation of high-quality nanoemulsions and “clean label” food.

• Our recently-released, next-generation Barocycler 2320EXTREME instrument was named a finalist in the prestigious 2017 R&D 100 Awards. Known as the “Oscars of Innovation”, the R&D 100 Awards recognize the top 100 revolutionary technologies of the past year.

• Professor Ruedi Aebersold, a worldwide expert in proteomics and one of PBI’s most well-known clients, received the prestigious Karger Medal for significant contributions to the development of new bioanalytical methods. In his acceptance speech, he discussed the importance of sample preparation and mentioned his use of the PCT Platform.

• Joseph L. Damasio, Jr. joined the Company as our full-time Chief Financial Officer and Vice President of Finance.

• Our Barocycler 2320EXTREME was named “Best New Instrument for Sample Preparation 2017” by Corporate America News (“Corp America”) as part of the publication’s 2017 North American Excellence Awards.

• We achieved CE Marking for our flagship instrument, the next-generation Barocycler 2320EXTREME. CE Marking permits PBI to begin sales of the 2320EXT to all 31 countries of the European Economic Area.

Mr. Joseph L. Damasio, VP of Finance and CFO of PBI, commented, “This past year was filled with a number of significant financial, operational and technological accomplishments that have set the stage well for what we believe will be a very exciting and successful 2018. Key among these accomplishments are the continued double-digit growth rates in our products and services area, the acquisition of the BaroFold patents, the continued maturation of our novel and now patented Ultra Shear Technology, the critical changes made to our flagship Barocycler 2320EXTREME that have enhanced this already very powerful instrument, the significant expansion of our sales and marketing capabilities, and the continued global recognition of the advantages of the PCT Platform in biological scientific studies.”

Mr. Damasio continued, “Although we had a successful 2017, we were nonetheless disappointed that our goal to up-list PBI to a national exchange did not happen last year. Because we understand the advantages and importance that an up-list will bring PBI, we anticipate re-initiating the up-list process soon, with a goal to complete the up-list before the end of this year.”

Mr. Richard T. Schumacher, President and CEO of PBI, commented, “We believe that the accomplishments of the past several years have set the stage well for future success. Our technology is now more powerful, our customer base bigger, our product portfolio larger, our product applications more enhanced, our supporters more vocal, our capabilities stronger, and our desire to succeed has never been more focused and determined. We remain very, very excited about 2018.”

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Tuesday, April 3, 2018. To attend this teleconference via telephone, Dial-in: (877) 407-8031 (North America), (201) 689-8031 (International). Verbal Passcode: PBIO Fourth Quarter and Fiscal Year 2017 Financial Call, ID 27377.

Replay Number (877) 481-4010; (919) 882-2331 (International). Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company’s financial results for the year ended December 31, 2017 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Joseph L. Damasio, VP of Finance and CFO (508) 230-1829 (F)

$CIIX to Debut ‘Bitcoin Big Winner’ Program on Phoenix North America Chinese Channel

April 3, 2018

• Reinforcing its focus on cryptocurrency and TV broadcasts, CIIX recently unveiled plans to broadcast a daily commentary titled ‘Bitcoin Big Winner’ on the Phoenix North America Chinese Channel
• CIIX broadcasts a live daily video show titled ’Bitcoin MultiMillionaire’ from the floor of the NYSE; company plans to explore cryptocurrency mining at datacenter near Seattle
• CIIX sponsored 2018 National Investment Bankers Association (“NIBA”) meeting in New York to meet with micro-cap and small-cap investors

ChineseInvestors.com, Inc. (OTCQB: CIIX) is reaching the global Chinese-speaking community with regard to bitcoin — with TV broadcasts, an online site, an ATM in the lobby of its San Gabriel, California, headquarters and plans to mine cryptocurrency from a datacenter near Seattle. The company is exploring cryptocurrency mining following its recent purchase of mining machines (http://cnw.fm/VL4nB).

CIIX recently sponsored the 2018 NIBA meeting in New York, a conference for small-cap and micro-cap investors, providing an opportunity to present its recent developments. A video interview with CEO Warren Wang is currently available on NIBA’s website, during which Wang highlights CIIX’s future plans.  According to company data, NIBA’s members have cumulatively raised $15 billion in new capital for emerging growth companies, and the organization is responsible for 90 percent of all IPOs under $20 million.

Aiming to capitalize on rising interest in cryptocurrencies and their underlying blockchain technology, CIIX recently revealed that it plans to debut a new daily commentary show titled ‘Bitcoin Big Winner’ on the Phoenix North America Chinese Channel. The channel currently features 24/7 news, in-depth financial reports and live interviews highlighting the Chinese community throughout North America. It is available on major satellite, cable and IP television platforms (http://cnw.fm/9eO27).

CIIX is employing all forms of media to reach its audience about cryptocurrency news. It broadcasts ‘Bitcoin MultiMillionaire’, a daily video emanating from the New York Stock Exchange. The company also maintains a website, NewCoins168.com. Additionally, it hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters, and it recently purchased equipment to mine for cryptocurrencies, such as bitcoin and Litecoin, at a databank located near Seattle.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

• Infusion of Biotechnology Into Cannabis Market Leads to Booming Growth
• Medical Cannabis Payment Solutions’ (REFG) ‘Green’ is the Medical Cannabis Electronic Transaction Solution
• Global Payout, Inc. (GOHE) Financial Solutions Link World Companies of All Sizes

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$CHCI Announces Major Shift of Business Focus

WASHINGTON and RESTON, Va., April 02, 2018 — Comstock Holding Companies, Inc., (NASDAQ:CHCI) (“CHCI” or the “Company”), today announced it will be transitioning its business strategy and operating platform from for-sale homebuilding to commercial development, asset management and real estate services. Anchoring the transition is a long-term asset management agreement entered into by a wholly owned subsidiary of CHCI and privately held entities that own multiple mixed-use developments and stabilized assets at key Metro stations on Washington DC Metro’s Silver Line, which upon completion in 2020, will connect Dulles International Airport and Loudoun County to Tysons Corner and downtown Washington, DC. The assets under management (“AUM”) covered by the initial asset management agreement will at full build out include more than 5 million square feet of investment-grade, mixed-use assets encompassing more than 2,500 multi-family rental units, Class A and Trophy office, retail and entertainment buildings, hotels, and parking garages located adjacent to Silver Line Metro Stations; representing an estimated AUM value of $2.5 to $3.0 Billion.

Ownership of the portfolio of assets covered by the initial asset management agreement includes the Company’s Chairman/CEO and largest individual shareholder, Christopher Clemente, a prominent high net worth family office, and Daito Trust Construction, Ltd., one of the largest publicly traded Japanese developers and managers of multi-family assets.

The transition of the Company’s business platform represents the integration of the previously separate for-sale homebuilding operating platform of CHCI and the commercial development operating platform of Mr. Clemente’s private company into one public company: CHCI. The combination leverages the diverse capabilities and relationships developed over more than 30 years of Comstock’s commercial and residential development operations in the Washington, DC metropolitan area. The enhanced operating platform of CHCI will be service focused, transitioning from an on-balance sheet for-sale homebuilder into an asset manager of investment-grade commercial real estate assets and provider of real estate services operating through two real estate focused platforms:

• CDS Asset Management (“CAM”) will provide real estate development, asset management and property management services.
• Comstock Real Estate Services (“CRES”) will provide development supply chain services including capital markets, real estate brokerage, environmental consulting and design services.

“The shift from a for-sale homebuilding operation to a fee-for-service asset management model positions CHCI for greater financial stability, profitability and growth,” said Christopher Clemente, Chairman and Chief Executive Officer of CHCI.  “The transition will result in a substantial reduction in short-term and long-term debt; enhancing the overall financial profile of CHCI in the near term as we complete the majority of our for-sale homebuilding projects by year-end 2018, while also positioning CHCI to benefit from tremendous growth taking place in the Dulles Corridor of Fairfax County and Loudoun County.  With our initial asset management agreement in place, CHCI is positioned to expand AUM revenue through the development of multiple properties in markets experiencing high-demand for mixed-use, transit-oriented properties that have entitlements substantially in place, while pursuing additional growth in AUM and pursuing service based revenue growth through CRES.  We anticipate additional announcements in the coming months that will provide shareholders with additional details regarding our new business focus as well as visibility to the long-term growth prospects of CHCI.”

A detailed discussion of the Company’s strategic approach to creating value is covered in the Company’s latest investor relations presentation, which can be found at www.ComstockCompanies.com.

About Comstock Holding Companies, Inc.
CHCI is a multi-faceted real estate development, asset management and real estate related services company that, since 1985, has designed, developed, constructed and managed several thousand residential units and millions of square feet of residential and mixed-use projects throughout the Washington, DC metropolitan market and in other key markets in the southeastern United States. In early 2018, CHCI transitioned its operating platform from being primarily focused on developing on-balance sheet, for-sale, homebuilding projects to being focused on commercial real estate development, asset management and real estate related services. As a result, CHCI began operating through two real estate focused platforms, CDS Asset Management (“CAM”) and Comstock Real Estate Services (“CRES”). CAM provides real estate development, asset management, and property management services, while CRES provides development supply chain services, including capital markets, real estate brokerage, environmental consulting and design services in the Washington, DC metropolitan area and in New Jersey and Pennsylvania. Anchoring the transition of CHCI is a long-term asset management agreement covering two of the largest transit-oriented, mixed-use developments in the Washington, DC area; Reston Station, a 3 million square foot transit-oriented, mixed-use development located in Reston, VA, and Loudoun Station, a 2.5 million square foot transit-oriented, mixed-use development in Ashburn, VA, as well as other additional development assets. Comstock’s substantial experience in entitling, designing, developing, and managing a diverse range of properties including apartments, single-family homes, townhomes, mid-rise condominiums, high-rise condominiums and mixed-use (residential and commercial) properties, as well as large scale commercial parking garages and infrastructure projects, has positioned the Comstock organization as a premier developer and real estate related service provider in the mid-Atlantic Region. The Company is a publicly traded company, trading on NASDAQ under the symbol CHCI. For more information about CHCI or its businesses, please visit www.ComstockCompanies.com.

About Reston Station
Strategically located mid-way between Tysons Corner and Dulles International Airport, Reston Station is among the largest mixed-use, transit-oriented developments in the Washington, DC area. Located at the terminus of Phase I of Metro’s Silver Line, Reston Station is already home to more than 1,000 residents, numerous businesses, multiple retail establishments, and several restaurants. With more than 1 million square feet of completed and stabilized buildings, more than 2 million square feet of additional development in various stages of entitlement, development and construction, and a 3,500-space underground parking garage and transit facility adjacent to the Wiehle Reston-East Metro Station, the Reston Station neighborhood is taking shape and quickly becoming Fairfax County’s urban focal point in the Dulles Corridor. For more information about Reston Station, please visit; www.RestonStation.com

About Loudoun Station
Located at the terminus station on Metro’s Silver Line, minutes from Dulles International Airport, Loudoun Station represents Loudoun County’s first (and currently its only) Metro-connected development. Loudoun Station has approximately 700,000 square feet of mixed-use development completed, including hundreds of rental apartments, approximately 150,000 square feet of retail, restaurants, and entertainment venues, 50,000 square feet of Class-A office, and a 1,500-space commuter parking garage. More than 2 million square feet of additional development is slated for Loudoun Station.  Located adjacent to Metro’s Ashburn Station, the Loudoun Station neighborhood represents Loudoun County’s beginning transformation into a transit connected community with direct connectivity to Dulles International Airport, Reston, Tysons Corner and downtown Washington, DC. As Loudoun County’s only transit connected neighborhood, Loudoun Station has become the new downtown of Loudoun County in the Dulles Corridor. For more information about Loudoun Station, please visit; www.LoudounStation.com

Cautionary Statement Regarding Forward-Looking Statements
This release includes “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by use of words such as “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” “will,” “should,” “seeks” or other similar expressions. Forward-looking statements are based largely on our expectations and involve inherent risks and uncertainties, many of which are beyond our control. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made. Some factors which may affect the accuracy of the forward-looking statements apply generally to the real estate industry, while other factors apply directly to us. Any number of important factors which could cause actual results to differ materially from those in the forward-looking statements include, without limitation: our ability to successfully transition our business platform, including the winding down of our homebuilding business and our performance under the asset management agreement; completion of Comstock’s financial accounting and review procedures; general economic and market conditions, including interest rate levels; our ability to service our debt; inherent risks in investment in real estate; our ability to compete in the markets in which we operate; economic risks in the markets in which we operate, including actions related to government spending; delays in governmental approvals and/or land development activity at our projects; regulatory actions; fluctuations in operating results; our anticipated growth strategies; shortages and increased costs of labor or building materials; the availability and cost of land in desirable areas; adverse weather conditions or natural disasters; our ability to raise debt and equity capital and grow our operations on a profitable basis; and our continuing relationships with affiliates. Additional information concerning these and other important risk and uncertainties can be found under the heading “Risk Factors” in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, for the fiscal year ended December 31, 2017. Our actual results could differ materially from these projected or suggested by the forward-looking statements. Comstock claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements contained herein. Comstock specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Company:
Comstock Holding Companies, Inc.
Christopher Conover, 703-230-1985
Chief Financial Officer: Christopher Conover
Source: Comstock Holding Companies, Inc.

$SLS Positive Interim Data, Phase 2b NeuVax Clinical in Breast Cancer

Clinically meaningful activity in favor of investigational nelipepimut-S (NeuVax) + Herceptin arm

Clinically and statistically significant efficacy in triple negative breast cancer (TNBC) cohort; p=0.023

NEW YORK, April 02, 2018 — SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced positive interim data from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin®) +/- nelipepimut-S (NeuVax™)  in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.

A pre-specified interim analysis, conducted by an independent Data Safety Monitoring Board (DSMB) of the efficacy and safety data for the study in an overall population of 275 patients as well as the two primary study target patient populations (node-positive and TNBC) after a median follow-up of 19 months,  demonstrated a clinically meaningful difference in median disease-free survival (DFS) in favor of the active arm (NeuVax + Herceptin), a primary endpoint of the study, with hazard ratios of 0.67 and 0.61 in the intent to treat (ITT) and modified ITT (mITT) populations (i.e., those who received at least one dose of vaccine or control) as well as a 34.9% and 39.5% reduction in relative risk of recurrence in the active versus control arms in the ITT and mITT populations, respectively.

A clinically meaningful and also statistically significant difference was found between the two arms in the cohort of patients (n= 98) with triple-negative breast cancer (TNBC), with a hazard ratio of 0.26 and a p-value of 0.023 in favor of the NeuVax + Herceptin combination with a 70.4% reduction in relative risk of recurrence in the active arm versus control.  Similarly, a clinically meaningful and statistically significant difference was found between the two arms in favor of the combination in the cohort of patients not receiving hormonal therapy (n = 110), with a hazard ratio of 0.24 and a p-value of 0.009 with a 74.1% reduction in relative risk of recurrence in the active arm versus control. This pre-specified interim analysis also showed an adverse event profile with no notable differences between treatment arms.  The addition of NeuVax to Herceptin did not result in any additional cardiotoxicity compared to Herceptin alone.

“We are indeed excited about these compelling results and believe NeuVax + Herceptin has the potential to become an important therapeutic option for TNBC patients.  The positive NeuVax phase 2b data underscores the innovative science and approach we have taken to investigate this agent’s potential to address this persistent therapeutic challenge.  We plan to immediately engage with the FDA and EMA, as per the recommendation of the DSMB, to identify the optimal path forward in this particular patient group, while advancing the drug through a partnership or other strategic collaboration,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “These are indeed unique and exciting clinical data for TNBC patients, and I would like to extend my sincere gratitude to all patients who have participated in this clinical trial, as well as the study teams.”

The NeuVax + Herceptin combination was found to be generally well-tolerated. The majority of treatment-emergent adverse events (TEAE) were of mild or moderate (G1/G2) severity and the majority of G3 systemic TEAEs were unrelated to NeuVax.  Treatment-related adverse events consisted primarily of manageable local injection site reactions, skin induration, pruritus and fatigue.

Additionally, in the NeuVax + Herceptin arm, in vivo HER2-specific T-cell immune responses (IRs), assessed by delayed type hypersensitivity (DTH) skin testing, showed a time-dependent increase in IR potency compared to the earliest tested datapoint (p=0.000023), while no such increase was observed in the control arm.

Based on the results above, the DSMB has recommended to expeditiously seek regulatory guidance by the FDA for further development of the combination of NeuVax + Herceptin in TNBC, considering the statistically significant benefit of the combination therapy seen in this population with large unmet medical need.

“We are very pleased with these findings, which suggest that NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low-to-intermediate HER2-expression, especially given the recent report of the NSABP B-47 trial showing no benefit in these patients with Herceptin alone.  Furthermore, our trial has shown a significantly improved disease-free survival in women with TNBC.  The favorable findings for this cohort are particularly promising, given the limited treatment options for these patients with high risk of recurrence and death,” commented COL (ret) George E. Peoples, MD, FACS, the study director and sponsor-investigator of the IST. “We look forward to presenting these data at an upcoming major medical conference and to supporting SELLAS in the regulatory and developmental pathway for NeuVax.”

Herceptin^® is a registered trademark of Genentech, Inc. and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.

About the NeuVax + Herceptin study

This Phase 2b trial is a multi-center, randomized, single-blinded, placebo-controlled trial in 275 HER2 1+/2+ breast cancer patients with positive nodes and/or TNBC. The study combines NeuVax and trastuzumab (Herceptin) in the adjuvant setting aiming to prevent recurrence or death. Tumors in these women show low levels of expression of HER2, as measured by immunohistochemistry (IHC), i.e., at a level of either 1+ or 2+ and, hence, these patients are not considered candidates for Herceptin. Patients who are hormone receptor-negative and HER2 1+/2+ by IHC are currently defined as ‘triple-negative’ breast cancer (TNBC) patients. NeuVax (nelipepimut-S) is a potentially first-in-class, HER2-directed cancer immunotherapy and is the immunodominant peptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) following binding to specific HLA molecules on antigen presenting cells (APC) and destroy HER2 expressing cancer cells.

About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.  GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications.  SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer.  SELLAS plans to study GPS in up to four additional indications.  SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the results of clinical studies and as to further development of nelipepimut-S (NeuVax) for breast cancer. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with immune-oncology product development and clinical success thereof, uncertainties related to timing and ability to obtain needed shareholder consent in a timely manner, the uncertainty of regulatory approval, the uncertainty of partnering its clinical assets, and other risks and uncertainties affecting SELLAS and its development programs. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
ir@sellaslife.com

David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
info@sellaslife.com

$NETE Aims to Transform the Online and Mobile Payments Experience

April 2, 2018

• Point-of-sale terminals market expected to reach $116 billion by 2025 with a CAGR of 9.9 percent
• Appointment of seasoned fintech specialists to board of directors brings valuable domestic, international finance expertise to company
• Mobile commerce projected to account for 70 percent of ecommerce sales in China and India, while at least one-third of retail sales in the U.K., Germany and the U.S. will stem from ecommerce

Global technology and value-added solutions company Net Element, Inc. (NASDAQ: NETE) has thrived on developing innovative ideas into marketable solutions that engage users in various segments of the highly competitive global ecommerce marketplace (http://nnw.fm/3eKay). Value-added transactional innovations such as Aptito, an all-in-one iOS cloud-based restaurant management and payment acceptance solution, along with ecommerce and retail payment transaction and processing brands such as PayOnline and Unified Payments, add convenience and alternatives to cash payments for retail transactions.

A surge in demand for wireless technologies and the rise of ecommerce is expected to drive the overall global point-of-sale terminals market to a whopping $116 billion by 2025, according to Grand View Research (http://nnw.fm/immR6). An article in Entrepreneur notes that there are numerous advantages underpinning the transition from a society that favors plastic bankcards to a marketplace that allows consumers to pay through their mobile devices (http://nnw.fm/E3Quf). Chief among these are ease of transactions, greater security and heightened convenience. In addition, mobile payments can be a real timesaver, which makes them seriously attractive for millennials (http://nnw.fm/0lF0c).

In a news release, Jonathan Fichman, the newest member of Net Element’s board of directors (http://nnw.fm/zXzm9), said, “The company’s recently announced plans to create a blockchain payments platform and its recently released next generation cloud-based point of sale payments system will both be impactful innovations for the industry.”

Fichman, whose 20-plus years of strategic domestic and international finance expertise within Fortune 100 companies includes extensive experience in fintech, payments, blockchain, wealth management and banking, joins Jon ‘Dr. J’ Najarian, who was also recently appointed to the board. Najarian, a professional investor, money manager and media analyst, is also a CNBC personality (regularly appearing on the ‘Halftime Report’ and ‘Fast Money’ programs) (http://nnw.fm/yKW6i) and a former linebacker for the Chicago Bears.

The global ecommerce market reached $2.3 trillion in 2017, and it’s expected to soar to a ‘mind-boggling’ $4.5 trillion by 2021, according to a Statista report (http://nnw.fm/lg9tK). Another industry perspective notes that mobile commerce will account for more than 70 percent of ecommerce sales in both China and India in 2017, with mobile commerce accounting for a full third of total retail ecommerce sales in the U.K., Germany, and the U.S (http://nnw.fm/8IdUS).

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes, applying multi-channel platforms, all-in-one digital solutions and end-to-end encryption of cardholder data that utilizes tamper-resistant hardware to ensure integrity and simplify security. Net Element was ranked number 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• SmartCash ($SMART) and the Future Potential of SmartCard
• First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) Announces Positive Cobalt Mineralization in Assay Core Samples
• IEG Holdings Corp. (IEGH) Delivering Loan Assistance to Underbanked Market

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX To Capitalize on Growing Demand for CBD-based Health Products

March 5, 2018

• CIIX announces spinoff of all hemp-related assets into a single private company
• CIIX shifts primary focus to core financial services, including cryptocurrency and blockchain technology

ChineseInvestors.com, Inc. (OTCQB: CIIX) has become the premier financial information website providing real-time market commentary, analysis and education-related services to Chinese-speaking investors. In 2018, the company is strategically focusing on building its core financial services business. CIIX has announced a spinoff of all hemp-related assets as the company explores new ways to expand.

CIIX announced plans to spin off all hemp-related assets into a single private company. CBD Biotechnology Co. Ltd., ChineseHempOil.com, Inc. and Hemp Logic Inc. will be combined into a single private company. Shareholders have the opportunity to take advantage of this dividend. CIIX CEO Warren Wang is encouraging holders of CIIX preferred stock to convert into common before May 31, 2018, the date of the spinoff.

The subsidiaries are well positioned to achieve significant growth. This spinoff is part of the groundwork to capitalize on the growing demand for CBD-based nutrition and health products in the U.S. and China. In January, these subsidiaries made a combined $100,000. The progress of the newly formed company will be overseen by CIIX, but the spinoff of CBD-focused assets will allow CIIX to focus on core financial services, including cryptocurrency and blockchain technology.

Since 1999, CIIX has been leading the way in providing financial information and education for Chinese-speaking investors. With the formation of the new company, CIIX plans to focus on its new cryptocurrency division and core financial education business, including ‘Bitcoin MultiMillionaire’, a daily newscast broadcast by CIIX as a free bitcoin education site in the Chinese language. The broadcast was launched in recognition of the growing interest in cryptocurrency among Chinese investors. CIIX provides reliable market information to help investors make informed decisions to meet their personal financial goals.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

• Medical Cannabis Payment Solutions’ (REFG) ‘Green’ is the Medical Cannabis Electronic Transaction Solution
• Global Payout, Inc. (GOHE) Financial Solutions Link World Companies of All Sizes
• Marijuana Company of America, Inc. (MCOA) Leading the Way in the Cannabis and Hemp Industry

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net